

FDA Patient Affairs Staff

How FDA Involves Patient Advocates

Susan Chittooran, MSW

#OCEPIP19

Patient Affairs Staff
Office of Clinical Policy and Programs
Office of the Commissioner

October 8, 2019

Overview

I

**About
Patient
Affairs**



II

**FDA
Listening
Sessions**



III

**FDA Patient
Representative
Program**



IV

Questions





Patient Affairs Staff

Who We Are & What We Do


The Importance of the Patient Voice



- Provide insight on issues, concerns, needs and priorities that are important to patients and caregivers
- Have diverse opinions and experiences
- Provide insights on risk tolerance and potential benefit
- Provide real world experience

Patients are at the heart of FDA's work

Evolution of Patient Engagement at FDA



Patient Engagement Across FDA



- **FDA Patient Affairs Staff:**

PatientAffairs@fda.gov

- FDA Patient Representative Program:


FDAPatientRepProgram@fda.hhs.gov

- Patient Engagement Meeting Requests:

CDRH_PatientMeetings@fda.hhs.gov

- CDRH's Division of Industry and Consumer Education:

DICE@fda.hhs.gov



- CBER's Patient Engagement Initiatives:
CBERPatientEngagement@fda.hhs.gov

- Office of Communication, Outreach and Development:
OCOD@fda.hhs.gov

- Professional Affairs and Stakeholder Engagement:
CDERPASE@fda.hhs.gov

- CDER Division of Drug Information:
DrugInfo@fda.hhs.gov

- Patient Focused Drug Development:
patientfocused@fda.hhs.gov

Patient Affairs Staff (PAS)



Who we are



What we do

Patient Affairs Staff (PAS) in the **Office of the Commissioner** leads patient engagement activities **across the medical product Centers**—to allow dialogue and collaboration between patients, their advocates, and the FDA

- Creating and assisting with **public-private collaborations and partnerships**
- Lead **cross-cutting programs and activities** that leverage best practices and enhance patient engagement.
- Enhancing FDA's **external communication platforms** (e.g., FDA's *For Patients* webpage, social media, etc.)

Patient Affairs Staff (PAS)

- FDA & EMA Patient Engagement Cluster
- Patient Engagement Collaborative
- FDA Rare Disease Listening Sessions
- FDA Patient Council



Our Programs
and
Initiatives



Enhancing Communication With Patients



U.S. FOOD & DRUG ADMINISTRATION

Home > For Patients > Learn About FDA Patient Engagement

Initiatives for Patients to Engage With FDA

SHARE TWEET LINKEDIN PIN IT EMAIL PRINT

Initiative	FDA-led Patient-Focused Drug Development (PFDD) Meetings	Externally-led PFDD Meetings	NORD MOU Pilot Listening Sessions	Patient Engagement Collaborative	Patient Engagement Advisory	Patient Representative Program (PRP)
Purpose	Public meetings that systematically obtain the patient perspective on specific diseases and their	To allow patient organizations to identify and organize patient-focused collaborations to generate	Pilot listening sessions in new diseases to inform FDA staff of disease and treatment	A	dis	ab

U.S. FOOD & DRUG ADMINISTRATION

Home > For Patients > Learn About FDA Patient Engagement

For Patients

approvals, and learn what FDA is doing of new drugs to treat or prevent cancer.

U.S. FOOD & DRUG ADMINISTRATION

Home > For Patients > Learn About FDA Patient Engagement

Patients Matter Video Series


SHARE TWEET LINKEDIN PIN IT EMAIL PRINT


The Patients Matter Video Series is a series of short videos developed by FDA's [Patient Affairs Staff](#) to teach patients and other stakeholders about FDA and patient engagement efforts. The video series is intended to educate patients and other stakeholders about FDA, encourage them to share their perspectives on living with a disease or condition, and provide information about how to contact the Agency.



Submit Questions & Meeting Requests





 **U.S. FOOD & DRUG**
ADMINISTRATION


Search FDA 

Request to Connect


This form is intended for use by individual patients, caregivers, advocates, patient groups, and health professionals to encourage understanding and participation in FDA's regulatory work. This form is not for use by industry stakeholders. Requests may be related to a drug, biologic, device or a combination thereof. To submit your question or to request a meeting please complete the form below and click "Submit".

Please tell us who you are (required):

Individual Patient, Caregiver or Advocate  Patient Group 

Health Professional  Other

Question or Meeting Request (required):

Question Meeting Request 

Submit

www.fda.gov/RequestToConnect

FDA Rare Disease Listening Sessions

FDA Patient Listening Sessions



Rare Diseases Pilot

- Memorandum of Understanding with the National Organization for Rare Disorders (NORD)
- Inform regulatory decision-making
- Educate review staff about rare diseases
- Help patients and their advocates understand the FDA's mission and work
- Assess the value & establish a process document
- Provide a starting point to inform early stage research & development



Understanding FDA Rare Disease Listening Sessions



What are Listening Sessions?

✔ ARE

- **Non-public, non-advisory** discussions between FDA staff and **patients, their caregivers, and/or their advocates**
- **1 to 2 hour** meetings
- Via **phone, in person** at FDA or a **mix of the two**
- Meant to facilitate **expeditious sharing of patient or advocate perspectives** on:
 - Disease burden
 - Treatment burden
 - Impact on daily activities
 - Priorities to consider in medical product development programs

✘ Are NOT

- Open to **industry**
- Avenues for the endorsement of **specific medical products**
- Able to guarantee **representative or comprehensive perspectives** on disease or treatment burden
- Meant to take the place of **other patient input and engagement processes**, e.g., the FDA Patient Representative Program, Patient-Focused Drug Development (PFDD) Meetings

FDA Rare Disease Listening Sessions



Two Types:

1. FDA-requested: specific set of questions to ask of a particular patient sub-population
2. Patient-requested: patient community wants to share their experiences and perspectives with the FDA

www.fda.gov/RequestToConnect

FDA Rare Disease Listening Sessions



Previously Conducted Listening Sessions



FDA Review Division-Requested Listening Sessions

May 13, 2019 - Sanfilippo Syndrome

February 20, 2019 - Celiac Disease

December 4, 2018 – Fabry Disease

October 23, 2018 – Gene Therapy as a Treatment Modality for Hemophilia

Patient-Requested Listening Sessions

September 17, 2019 – Osteogenesis Imperfecta (OI)

August 7, 2019 - Osteoarthritis (OA)

June 13, 2019 - Neurofibromatosis (NF)

May 29, 2019 - Fibrodysplasia Ossificans Progressiva (FOP)

January 16, 2019 - Amyotrophic Lateral Sclerosis (ALS)

November 5, 2018 - Biliary Atresia, Progressive Familial Intrahepatic Cholestasis, Wilson's Disease

FDA Patient Representative Program

FDA Patient Representative Program SM



FDA Patient RepresentativeSM consultants provide direct input to the Agency’s decision-making process in over 300 diseases and conditions and participate on FDA Advisory Committees and in review division assignments.

Criteria for becoming an FDA Patient Representative:

-  **Know your disease**
-  **Be active in the community**
-  **Know your treatment**
-  **Avoid conflicts of interest**
-  **Remain objective**
-  **Be able to discuss your views**



Peg Ford

FDA Patient Representative

When a Patient Speaks Video

When a Patient Speaks Video Link

Link to Peg Ford Experience Ovarian Cancer video You Tube (Time 2 mins 20 seconds)

[https://www.youtube.com/watch?v=UVan4qU27XA&feature=youtu.be.](https://www.youtube.com/watch?v=UVan4qU27XA&feature=youtu.be)

FDA Patient Representative Program

What is the FDA Patient Representative Program?

Mechanism for advocates (patients and caregivers) to provide formal input to the Agency's decision-making process as medical products (drugs, biologics, and medical devices) are regulated.





FDA Patient Representative Program

200 FDA Patient Representatives with 300-500 diseases/conditions/device experiences

- AIDS/HIV
- Alzheimer's Disease
- Asthma
- Breast implants
- Cancer (various)
- Cardiovascular disease
- Cerebral Palsy
- Crohn's disease
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Diabetes
- Diabetes (insulin pumps)
- Fabry Disease
- Hepatitis B / Hepatitis C
- Infantile Spasms
- Lung Transplantation
- Lupus
- Lysosomal Acid Lypase Deficiency
- Major Depressive Disorder
- Muscular Dystrophy
- Nicotine Replacement Therapy
- Opioid Use
- Organ transplantation
- Parkinson's Disease
- Pompe Disease
- Sickle Cell Disease
- Short Bowel Syndrome
- Temporomandibular joint disorder

FDA Patient Representative Program

Two Primary Ways

FDA Patient Representatives Engage with FDA

1. Serve on FDA Advisory Committees
2. Consult with FDA Review Divisions



What CRITERIA Do We Use?

- Personal experience with the disease or condition (patient or caregiver).
- Advocacy experience: active with patient community and understands issues and concerns.
- Knowledgeable about treatment options and research.
- Analytical and objective: should grasp basic scientific principles and issues.
- Good communications skills: comfortable with public speaking.
- Commitment to serve: reliable
- Remain unbiased and unconflicted: activities and roles should not conflict with assignment—financial, appearance, ethical considerations.

When in doubt...contact Patient Affairs!



PatientAffairs@fda.gov



301-796-8460



www.fda.gov/Patients



@FDAPatientInfo

www.fda.gov/RequestToConnect